CMOPF (Cosmo NV) Other Financing: $-5.2 Mil (TTM As of Dec. 2025)


CMOPF Cosmo NV CMOPF
79 GF Score
Price $83.00
GF Value $54.89
Valuation Significantly Overvalued
! 3 Warning Signs
View Full Analysis

What is Cosmo NV Other Financing?

Cosmo NV CMOPF 79 Other Financing is $-5.2 Mil as of Dec. 2025. GuruFocus rates CMOPF with a GF Score™ of 79/100 and a GF Value™ of $54.89 (Significantly Overvalued). The stock has 3 warning signs investors should review.

Cosmo NV's Other Financing for the six months ended in Dec. 2025 was $0.0 Mil.

Cosmo NV's Other Financing for the trailing twelve months (TTM) ended in Dec. 2025 was $-5.2 Mil.

Cosmo NV Other Financing Historical Data

* Premium members only.

The historical data trend for Cosmo NV's Other Financing can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Cosmo NV Other Financing Chart

Cosmo NV Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Other Financing
Get a 7-Day Free Trial Premium Member Only Premium Member Only -5.51 -5.44 -7.15 -4.71 -5.27

Cosmo NV Semi-Annual Data
Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
Other Financing Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -195.23 -4.84 -33.61 -5.19 0.00
CMOPF
79GF Score
Cosmo NV CMOPF
Other Financing is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Cosmo NV Other Financing Calculation

Other Financing represents other cash flow from financing activity that not otherwise classified, which includes:
Proceeds From Stock Option Exercised
Other Financing Charges

Other Financing for the trailing twelve months (TTM) ended in Dec. 2025 adds up the semi-annually data reported by the company within the most recent 12 months, which was $-5.2 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Other Financing →
What does a Other Financing of $-5.2 Mil mean?
Cosmo NV (CMOPF) has a Other Financing of $-5.2 Mil as of Dec. 2025. Other Financing represents other cash flow from financing activity that not otherwise classified. View historical data for Cosmo NV and its competitors.
Is Cosmo NV's Other Financing too high?
Cosmo NV's current Other Financing is $-5.2 Mil. Overall, Cosmo NV has a GF Score™ of 79/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Cosmo NV's Other Financing compare to LLY and JNJ?
Cosmo NV's Other Financing of $-5.2 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Other Financing for a Drug Manufacturers company?
A good Other Financing depends on the Drug Manufacturers industry context. However, Other Financing should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Other Financing mean?
A high Other Financing can signal that a stock is expensive relative to its fundamentals. Other Financing represents other cash flow from financing activity that not otherwise classified. View historical data for Cosmo NV and its competitors. Cosmo NV's current Other Financing is $-5.2 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Cosmo NV stock overvalued right now?
Based on GuruFocus' analysis, Cosmo NV (CMOPF) is currently considered Significantly Overvalued. The stock's GF Value™ is $54.89, compared to a current price of $83.00 — trading 51.2% above its estimated fair value. The current Other Financing is $-5.2 Mil. Cosmo NV's overall GF Score™ is 79/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Other Financing calculated?
Other Financing is calculated from a company's financial statements. For Cosmo NV (CMOPF), the current Other Financing is $-5.2 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Cosmo NV (CMOPF) Overvalued in 2026?

Based on GuruFocus' analysis, Cosmo NV stock appears to be overvalued. The current stock price of $83.00 is trading 51.2% above its estimated GF Value™ of $54.89. GuruFocus considers Cosmo NV to be Significantly Overvalued.

Key valuation signals for CMOPF:

  • Other Financing: $-5.2 Mil
  • GF Value™: $54.89 vs. price of $83.00 (51.2% above fair value)
  • GF Score™: 79/100 with 3 warning signs

No single metric tells the full story. See the CMOPF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Cosmo NV Business Description

Address 91/94 North Wall Quay, 7th Floor, One North Dock, Dublin, IRL, D01 H7V7
Cosmo NV is is a life sciences company. The company is focused on MedTech AI, dermatology, gastrointestinal diseases, and contract development and manufacturing (CDMO). The company designs, develops, and manufactures solutions to address critical medical needs. Its technologies are trusted by international pharmaceutical and MedTech companies and reach patients and healthcare providers around the world. The product pipeline includes Eleview, GI Genius, Winlevi, Lialda, Uceris, and others.
79GF Score

Get the complete analysis for CMOPF

Other Financing is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$83.00
Price
$54.89
GF Value